Article
The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response.
Translational psychiatry - 21 Apr 2015
Biernacka J M, Sangkuhl K, Jenkins G, Whaley R M, Barman P, Batzler A, Altman R B, Arolt V, Brockmöller J, Chen C H, Domschke K, Hall-Flavin D K, Hong C J, Illi A, Ji Y, Kampman O, Kinoshita T, Leinonen E, Liou Y J, Mushiroda T, Nonen S, Skime M K, Wang L, Baune B T, Kato M, Liu Y L, Praphanphoj V, Stingl J C, Tsai S J, Kubo M, Klein T E, Weinshilboum R
Abstract excerpt
Response to treatment with selective serotonin reuptake inhibitors (SSRIs) varies considerably between patients. The International SSRI Pharmacogenomics Consortium (ISPC) was formed with the primary goal of identifying genetic variation that may contribute to response to SSRI treatment of major depressive disorder. A genome-wide association study of 4-week treatment outcomes, measured using the 17-item Hamilton...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.